Introduction
As the preferred choice to prevent various kinds of infectious diseases, such as influenza, hepatitis B, and tuberculosis, vaccination plays an indispensable role in controlling the dissemination of viruses or bacteria and reducing morbidity and mortality. Although traditional immunization methods (intramuscular and subcutaneous) can induce systemic immunoresponses, these methods are insufficient to evoke strong local immunity, particularly to elicit specific antibody responses in the mucosal region, which is the first barrier of defense against microorganisms. 1 The nasal cavity has been proven to be a promising and attractive choice for mucosal immunization. As the first line of defense against inhaled viruses, nasopharynx-associated If antigens are inhaled and adsorbed on the surface of nasal mucosa, active antigen-presenting cells (APCs) under epithelial cells will recognize, phagocytize, and present them to lymphocytes to induce their differentiation, proliferation, and activation. 4 However, soluble and nonadherent antigens can not only be blocked by the tight mucus and epithelial cells but also have low immunogenicity. 5 FluMist Quadrivalent, the only type of intranasal vaccine approved against influenza, was reported by NBC News to show low treatment effectiveness (46%-58% efficiency during the 2015-2016 season), as well as various side effects.
Nanosized biomaterials, such as nanoparticles, nanoemulsions, liposomes, and nanogels, of pathogen-like size can provide a platform for soluble antigens to sustain long-lasting release. Antigens carried by nanosized biomaterials can be easily recognized by APCs, thus inducing more effective immunoresponse. 6, 7 Therefore, an effective vaccine formulation or delivery system would enhance the stability, adhesive capacity, and immunogenicity of antigens, providing strong mucosal and systemic immunity. As such, the development of a new generation of nasal mucosal vaccination strategies is necessary. [8] [9] [10] [11] Curdlan, an extracellular polysaccharide with a simple linear β-1,3-glucan structure, specifically recognizes the dectin 1 receptor on the surfaces of various immune cells. 12 Recent research has shown that curdlan can activate dendritic cells through dectin 1 and TLR4. 13 Compared to aluminum adjuvant, curdlan sulfate (CS), a soluble derivative of curdlan, shows satisfactory immunoenhancement activity in vitro 14 and the ability to elicit stronger cellular and humoral responses in immunized mice. 15 CS also displays an antipathogen capacity in vitro and in vivo. 16, 17 Therefore, CS is a satisfying candidate for an immunoadjuvant. However, the negatively charged polysaccharide is hardly adsorbed by epithelia, which limit the applications of CS in mucosal immunotherapy.
Chitosan is the only alkaline polysaccharide found in nature and has been used as a mucosal absorption promoter for many years. 18, 19 Trimethylated chitosan as a drug carrier can assist many types of protein drugs across the mucosal barrier. 18, [20] [21] [22] [23] [24] [25] O- propyl-3-trimethyl ammonium chitosan chloride (O-HTCC) is a novel quaternized chitosan that facilitates the delivery of proteins or peptides. 26, 27 Sun and Wan 28 reported that O-HTCC could form nanoparticles with sodium tripolyphosphate by an ionic gelation method. The nanoparticles showed high loading efficiency and loading capacity for bovine serum albumin.
In this study, cationic O-HTCC was chosen to carry and internalize the model antigen ovalbumin (Ova). CS as an immunologic stimulant and cross-linking agent interacted with O-HTCC to form CS/O-HTCC nanoparticles. The Ova-loaded nanoparticles (called Ova/CS/O-HTCC) were characterized by several methods to evaluate size, charge, Ova-loading efficiency, and cellular uptake. The potential of CS/ O-HTCC as a nasal mucosal immunoadjuvant was evaluated with BALB/c mice (Scheme 1) by analyzing the activation and maturation of APCs, detecting the proliferation and differentiation of lymphocytes, and evaluating the expressions of antigen-specific antibodies in serum and mucosal lavage fluid after intranasal immunization.
Materials and methods
This work was performed in the Institute of Biochemical and Biotechnological Drugs and the Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University.
Materials
Chitosan (molecular weight [MW] 100 kDa, .90% degree of deacetylation) was obtained from Haidebei Marine Bioengineering (Jinan, China). Curdlan (MW 100 kDa) was supplied by Zhongke Biotechnology (Weifang, China). Ova, glycidyl trimethylammonium chloride (GTMAC), and a sulfur trioxide-pyridine complex were purchased from Sigma-Aldrich (St Louis, MO, USA). Alhydrogel adjuvant 2% (aluminum hydroxide gel) was obtained from InvivoGen (San Diego, CA, USA). MTT and fluorescein isothiocyanate (FITC) were obtained from Solarbio Bioscience and Technology (Shanghai, China). Neutral red was supplied by Sangon (Shanghai, China). Goat antimouse HRP-conjugated IgG, IgG 1 , IgG 2a , and IgA were purchased from Abcam (Cambridge, UK). IFNγ and IL4 enzyme-linked immunosorbent assay (ELISA) kits were supplied by Bio-Swamp (Wuhan, China). Antimouse FITC-CD3, APC-CD4, FITC-CD4, PE-CD8a, PE-CD69, PE-F4/80, PE-CD11c, FITC-CD40, FITC-CD86, and FITC-major histocompatibility complex (MHC)-II were purchased from Thermo Fisher Scientific (Waltham, MA, USA). All other chemicals used were of analytical grade.
Preparation of cs
CS was prepared from curdlan as previously described by Li et al, 14 with a slight modification. Briefly, 4 g curdlan was dissolved in 400 mL dried dimethyl sulfoxide by magnetic stirring overnight at room temperature. After curdlan had been completely dissolved, the temperature of the solution was adjusted to 65°C, and 10 g sulfur trioxide-pyridine complex was added to the solution and mixed for 1 hour. Then, the reaction solution was cooled below 30°C in ice water bath. Methanol (2 L) with 5% sodium acetate was added, and the reaction rested at room temperature for 4 hours to precipitate the product. After filtration, the precipitate was washed twice using methanol and dissolved in water. Then, the solution was desalted using ultrafiltration through a membrane with an MW cutoff of 5 kDa and dried in a vacuum-freezing dryer to obtain CS. The structure of CS was confirmed by Fourier transform infrared (FT-IR) spectroscopy. The sulfur contents of CS were analyzed using an Elementar Vario EL III analyzer.
Preparation of O-hTcc
O-HTCC was synthesized according to a previously established method, 25, 26 with some modification. Chitosan (9 g, MW 100 kDa) was dissolved in 300 mL 10% (v:v) acetic acid aqueous solution at 40°C. After chitosan had completely swelled, 47.4 g of benzaldehyde was added dropwise, and the solution stirred for 1 hour until a uniform milky colloid formed. After removing part of the solvent at 60°C (in a vacuum) overnight, the pH of the reaction product was adjusted to 7 with 1 M NaOH. To obtain N-benzal chitosan, the precipitate was filtrated, washed twice with methanol, and dried overnight. Then, the precipitate was dissolved in 150 mL isopropyl alcohol by stirring at 70°C. After that, 27 g GTMAC was added dropwise into the solution. The reaction was run for 16 hours, followed by filtration. The precipitate was washed, dried, and added to 150 mL 0.25 mol/L HCl ethanol solution with stirring at room temperature for 24 hours. After most of the ethanol had been removed using a rotary evaporator, 500 mL methanol was mixed into the solution and the solution rested overnight to precipitate the product. The product was washed and dissolved in water. To remove impurities and concentrate, an ultrafiltration system equipped with a membrane with an MW cutoff of 5 kDa was used. Then, lyophilization was performed to obtain O-HTCC.
The reaction process was monitored by FT-IR spectroscopy. 1 H nuclear magnetic resonance (NMR) spectroscopy was used to confirm the identity of the final product. The degree of quaternization was calculated:
where (CH 3 ) 3 is the peak area of the methyl protons of the trimethylammonium group and H is the peak area of the proton of the anomeric -CH. assessment of antigen uptake in vitro
Ova and FITC were dissolved in sodium carbonate buffer (pH 9.5). FITC (1 mL, 1 mg/mL) was added dropwise to 1 mL Ova (10 mg/mL) aqueous solution under continuous stirring at 4°C in the dark. The reaction was run overnight, followed by termination with 0.007 g of NH 4 Cl. The product was finally purified by dialysis using dialysis tubing with an MW cutoff of 1 kDa at 4°C in the dark and lyophilized for 48 hours. FITC-Ova/O-HTCC and FITC-Ova/CS/O-HTCC nanoparticles were prepared using the same method as the Ovaloaded nanoparticles. Then, Calu3 cells (purchased from Suer Biological Technology, Shanghai, China) were seeded in a 96-well plate with 2×10 4 cells per well. FITC-Ova and FITCOva-loaded nanoparticles were added to each well and incubated for 2 hours to allow FITC-labeled protein to be taken up by the Calu3 cells. Uptake efficiency was observed using fluorescence microscopy. Fluorescence-intensity percentage was measured using flow cytometry. Individual fluorescence of 10,000 cells was collected for each group.
In vitro internalization of FITC-Ova-loaded complexes in APCs was also analyzed. First, resident peritoneal macrophages were obtained using a previously described method. 29 After disinfection, peritoneal cells of the mice were harvested by lavage of the peritoneum with 5 mL Hank's balanced salt solution. DC2.4 cell lines (maintained in our lab) and peritoneal macrophages were seeded in six-well plates. After incubation with the FITC-Ova and FITC-Ova-loaded complexes for 2 hours, internalization was measured using fluorescence microscopy.
Intranasal immunization and sample collection
Female BALB/c mice (6-8 weeks old, purchased from Vital River Laboratory Animal Technology, Beijing, China) were housed with free access to rodent chow and water at room temperature for 1 week before the study. The mice were randomly divided into seven groups, and each group comprised 10 mice. Animal experiments were approved by the Experimental Animal Welfare and Ethics Committee of Shandong University and performed following ethical guidelines for the care and use of animals. All mice were intranasally immunized on days 1, 15, and 29 with various formulations (Table S1 ). As shown in Table S1 , on days 14, 28, and 42, retro-orbital blood samples were collected and then rested for 2 hours at room temperature. The serum was separated by centrifugation and stored at -80°C for analysis. At 2 weeks after the final immunization, samples (ie, saliva, vaginal fluid, and spleens) were collected for further assays.
splenocyte proliferation assay
Splenocytes of mice in each group were prepared using a previously reported method 14 and seeded on the 96-well plates with 2×10 6 cells/well. After culturing for 12 hours at 37°C, cells were treated with 10 μg/mL Ova to stimulate for 48 hours. The rate of proliferation was measured using the MTT method.
lymphocyte transformation assay
Lymphocytes of mice were obtained and cultured as previously described. Lipopolysaccharide and concanavalin A were used to stimulate the transformation of the lymphocytes. After treatment for 48 hours, the ratio of proliferation was detected by MTT assay. 
Flow cytometry analysis of surface markers on immunocytes
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cs/O-hTcc nanoparticles in vaccination CD4, CD8, CD69, F4/80, CD11c, CD40, CD86, and MHCII) for 1 hour at 4°C in the dark. The cells were washed three times using PBS to remove free antibodies and processed into single-cell suspensions. The expression of surface markers was analyzed by flow cytometry.
Peritoneal macrophage proliferation assay
Resident peritoneal macrophages were obtained as previously mentioned and planted with 2×10 5 cells per well in 96-well plates. Cells were treated with 10 μg/mL Ova for 48 hours, and then their capacity for proliferation was measured by MTT assay.
Neutral red internalization experiment
Resident peritoneal macrophages were seeded in a 96-well plate with 2×10 5 cells per well and treated with 100 μL Ova (10 μg/mL) for 48 hours. Then, 0.1% (w:v) neutral red dissolved in Hank's balanced salt solution was added to each well, and the wells incubated for 30 minutes at 37°C. To remove excess dye, plates were washed three times using PBS at room temperature. Then, the supernatant was discarded and 100 μL of lysis buffer (50% ethanol/50% acetic acid) added to each well. After wells had stood for 3 hours, optical density at 540 nm was detected by a microplate reader.
Determination of cytokines in mouse sera by elIsa
To measure the expression of cytokines (IFNγ and IL4), serum was analyzed with the ELISA kits. Optical density at 540 nm was measured by a microplate reader. Concentrations of these cytokines were calculated by comparing with the standard proteins.
Determination of Ova-specific antibody levels in mouse sera
Expression of Ova-specific IgG, IgG 1 , IgG 2a , and IgA antibodies were detected by an indirect ELISA method. Briefly, after coating with a 5 μg/mL Ova solution (in 50 mM carbonate-bicarbonate buffer, pH 9.6) overnight, the 96-well plates were washed three times with PBS containing 0.05% Tween 20 by a microplate washer and then blocked with 200 μL 1% bovine serum albumin at 37°C for 2 hours. The serum of the mice in each group was proportionally diluted and added to the washed wells. The plates were then incubated for 1 hour at 37°C, followed by washing three times. Then, 100 μL diluted HRP-conjugated antibody (1:1,000) was added to the wells and incubated to react with Ova for 1 hour at 37°C. To determine the concentration of anti-Ova in serum, 50 μL 3,3′,5,5′-tetramethylbenzidine solution was added to the washed wells to generate chromogenesis for 10 minutes at 37°C. The reaction was terminated by adding 30 μL/well 2 M H 2 SO 4 , followed by measuring optical density at 540 nm.
Determination of Ova-specific sIgA production by elIsa
To evaluate the mucosal immunoactivity of the Ova/CS/ O-HTCC nanoparticles, saliva and vaginal lavage fluid were obtained. After centrifugation (4,000 rpm, 10 minutes), the supernatant was collected and tenfold diluted. Generation of Ova-specific secretory IgA (sIgA) in these samples were measured by ELISA using the aforementioned method.
statistical analysis
All quantitative data are expressed as mean ± SD. Oneway analysis of variance was used to determine statistical significance among various groups using GraphPad Prism software.
Results and discussion Preparation of cs and O-hTcc
Carbohydrates, such as curdlan and chitosan, have been shown to possess immunological activities. However, their poor solubility limits their biomedical applications, especially as adjuvants. These carbohydrates must be dissolved below pH 6, while many kinds of antigens, such as inactivated influenza virus, are unstable in acidic pH. 30 To overcome this obstacle, chemical modifications (such as sulfation and quaternization) of polysaccharides with inactive groups have been shown to be a potent strategy. Therefore, in this study, CS and O-HTCC were chosen to act as antigen delivery systems. First, a dimethyl sulfoxide-sulfur trioxide-pyridine system was used to modify curdlan with hydroxyl groups ( Figure 1A) . From the FT-IR spectra of curdlan and its sulfated derivative, as shown in Figure S1A , the characteristic peak at 1,225 cm -1 corresponding to asymmetrical S=O stretching indicated the presence of sulfate groups. A symmetrical C-O-S stretching-induced absorption peak was also observed at 815 cm -1 . In Table S2 , elemental analysis results showed that the extent of sulfation of CS was 13.738%. All the results confirmed that CS was successfully produced.
To improve the water solubility of chitosan, the quaternization reagent GTMAC was used to react selectively with the C-6-OH groups on 2-amino-protected chitosan ( Figure 1B) . Figure S1B shows the FT-IR results. In intermediate products O-HTCC to form a polyelectrolyte complex, this kind of complex exhibited considerably increased particle size and polydispersity-index values compared to Ova/CS/O-HTCC. These results indicate that CS with a high degree of substitution acted as a cross-linking agent to assemble the positively charged chitosan derivative tightly.
Generally, the amount of protein can be measured by bicinchoninic acid assay; however, we found that O-HTCC as an interfering substance affected the precision of the detection. Therefore, loading efficiency and release rate were measured by sodium dodecyl sulfate polyacrylamidegel electrophoresis and calculated by the band intensities.
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Zhang et al As shown in Figure S3 , Ova was efficiently adsorbed on the CS/O-HTCC nanoparticles (72.6%). After standing for 48 hours, the percentage of free Ova in the Ova/CS/O-HTCC and Ova/O-HTCC solutions increased from 37.7% to 83.9% and from 45.4% to 87.2%, respectively, which illustrated that the carriers provided sustained release of the protein without burst release (Figure 3) . Furthermore, the sodium dodecyl sulfate polyacrylamide-gel electrophoresis results confirmed the structural integrity of Ova in the nanoparticles, which was the key to maintaining the immunoregulatory activity of the antigens.
effect of cs/O-hTcc on cellular uptake ability of epithelial cells
Ingestion of antigens by nasal epithelial cells is the first step in nasal immunization. Many conventional antigen carriers may be hindered by dense mucus layers. 31 For example, negatively charged poly(lactic-co-glycolic acid) nanoparticles are not suitable for mucosal delivery. Although some mucoadhesive carriers can adhere to the mucus, they hardly penetrate the mucus layer. 32 Fluorescence microscopy confirmed that O-HTCC promoted the phagocytosis function of epithelium cells ( Figure 4A ), which was also confirmed by flow-cytometry analysis ( Figure 4B and C) . The CS/O-HTCC complex solution showed high viscosity, which indicated that is has the potential application as a mucoadhesive agent. Since the negatively charged cell surfaces hardly adhered and internalized FITC-Ova, O-HTCC interacted with the epithelial cells and induced a redistribution of cytoskeletal F-actin. As such, compared with the other nanocarriers, CS/O-HTCC nanoparticles, which are based on quaternized chitosan, 33 showed several advantages, including mucoadhesive capacity and permeation-enhancement properties. Based on the negative charge, CS stabilized the formation of nanoparticles and reduced the mucosal irritation induced by the cationic O-HTCC, while also neutralizing the cationic complex and slightly reducing uptake efficiency.
effect of cs/O-hTcc as a nasal immunization adjuvant on Ova-induced cellular immunoresponses
Once pathogens enter cells, cellular immunity, a protective immune process that involves the internalization of antigens, proliferation, and activation of antigen-sensitized lymphocytes and the release of cytokines, plays a crucial role in fighting against pathogen-induced infection. To investigate the potential activity of CS/O-HTCC as a nasal immunization adjuvant, we studied the effects of CS/O-HTCC on cellular immunoresponse of mice immunized with Ova.
Stimulation of lymphocytes by specific or aspecific mitogens promotes the production of lymphokines, followed by proliferation and differentiation of various effector cells, such as T lymphocytes and B lymphocytes. The effect of the polysaccharides on Ova-stimulated lymphocyte proliferation in immunized mice is shown in Figure 5A . The proliferation of lymphocytes in the mice immunized with Ova/CS/O-HTCC was significantly higher than that in other groups (P,0.001). Mouse nasal immunization with Ova/ CS/O-HTCC also showed strong capacity for T-lymphocyte and B-cell transformation ( Figure 5B and C) . Analysis of the T-lymphocyte subtypes in Figure 5D The activation of APCs, such as dendritic cells and macrophages, is indispensable in stimulating lymphocytes. Curdlan has been proven to activate dendritic cells and increase the production of cytokines through dectin 1 and TLR4. 13 Chitosan can activate the NLRP3 inflammasome of macrophages 34 and induce dendritic cell activation to promote T H 1-cell immunoresponses. In this study, the impact of the complexes upon the activation of APCs was studied.
As shown in Figure 6A , macrophages were stimulated by the polysaccharides, resulting in significant proliferation in all treatment groups, especially in the O-HTCC-related groups (Ova + O-HTCC group, CS + O-HTCC group, and Ova/CS/O-HTCC group). The phagocytic abilities of peritoneal macrophages extracted from immunized mice were detected by neutral red ingestion. Absorption values at 540 nm indicated that the number of absorbed particles significantly increased in the O-HTCC-related groups compared to the Ova group (P,0.001, Figure 6B ), while no apparent effect was observed for the coadministration of Ova and Alhydrogel (P.0.05 compared to Ova alone). F4/80 binding to macrophages has been proven to be a specific macrophage marker. 35 In this study, the proportion of F4/80-positive splenocytes indicated the recruitment of macrophages in the spleens of the immunized mice. As shown in Figure 6C , compared to Ova and Ova mixed with Alhydrogel, administration of the O-HTCC-related nanoparticles, especially Ova/CS/O-HTCC, induced a notable influx of macrophages in the spleen (P,0.001 compared to Ova alone, P,0.01 compared to Ova + Alhydrogel).
Internalization of the FITC-Ova in APCs was evaluated in vitro. The results in Figure S4 show that O-HTCC and CS/O-HTCC provoked cellular uptake of the dendritic cells and peritoneal macrophages. After absorbing and processing the antigens, activated APCs present peptides to CD4 + T cells by the MHCII molecule, the ligand for the T-cell receptor, while recognition of peptide MHCII is insufficient for the activation of Ag-specific CD4 + T cells. 36 As the costimulatory signal, CD40 induces the aggregation of MHCII molecules and the formation of the immunological synapse on APCs. 37 The upregulation of CD86, an initial ligand for CD28, can lead to T-cell activation. 38 The upregulation of CD11c indicates the transfer of dendritic cells to the spleen. Only the According to these results, CS/O-HTCC nanoparticles increased the influx of macrophages and dendritic cells into the spleen and improved phagocytosis, followed by activation of APCs to present peptides to T lymphocytes. After receiving the signal, inactive lymphocytes were activated and transformed to T H and T C cells with massive proliferation. Then, activated CD4 + T cells were chosen to regulate the immunoresponse.
Based on the secreted cytokines, effector CD4 + T cells can be divided into T H 1 and T H 2 cells. The T H 1 cells produce proinflammatory cytokines (such as IFNγ), which are responsible for the activation of macrophages and T C cells. In contrast, T H 2 cells produce IL4 and IL10 to promote humoral immunity. After analysis of the expression of IFNγ in serum, only Ova/CS/O-HTCC was shown to increase IFNγ concentration dramatically compared to PBS and Ova ( Figure 7A , P,0.05), which indicated that CS/O-HTCC nanoparticles enhanced the T H 1-type cellular immunoresponse to Ova. As specific T H 2-cell activators, Ova and Alhydrogel notably promoted the expression of IL4 ( Figure 7B , P,0.05 compared to PBS), indicating that CS was also apt to enhance the T H 2-type immunoresponse. According to these results, Ova/CS/O-HTCC significantly activated both T H 1-and T H 2-type cellular immunoresponses. However, compared to the Ova-induced T H 2 bias, Ova/CS/O-HTCC recovered the balance to some extent.
effect of Ova/cs/O-hTcc on promoting humoral immunoresponses
As effector molecules secreted by plasma cells, antibodies play an important role in the defense against extracellular microbes. IgG accounts for ~75% of the total immunoglobulins in plasma. A positive result was determined by a ratio of the absorbance of the tested (positive) serum and negative serum (P:N) of .2.1. The maximum dilution is called the titer of antibody for the antiserum when the P:N is $2.1. As shown in Figure 8A immunized with Ova/CS/O-HTCC produced a marked antibody response compared to the mice treated with Ova mixed with Alhydrogel (P,0.05).
IgA, a specific antibody produced by mucosal immunity, was also detected in serum ( Figure 8B ). Although the antibody titer was significantly higher in the Ova mixed with Alhydrogel-treatment group and Ova/O-HTCC-treatment group after the primary inoculum, mice receiving Ova/ CS/O-HTCC showed much higher levels of anti-Ova titers after the second and the third antigen inoculum (P,0.001 compared to Ova). Expression of the antigen-specific IgG 1 and IgG 2a subclasses was evaluated 2 weeks after the tertiary immunization. As shown in Figure 8C , in contrast to Ova and Alhydrogel, which only increased the production of effect of Ova/cs/O-hTcc on proximal mucosa and distal mucosa immunoresponse Site-specific integrins on sensitized mucosal immunocytes and the chemokines produced in vaccine-exposed mucosa impact the effector site. 39 After nasal mucosal immunization, an immunoresponse would occur directly in the mucosa of the 
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cs/O-hTcc nanoparticles in vaccination nasal cavity, as well as in the adjacent oral mucosa. Simultaneously, this immunization route also stimulates a strong vaginal mucosal immunoresponse. 40 As the key effector of mucosal immunity, sIgA was tested in the saliva and vaginal lavage fluid after 2 weeks of tertiary immunization ( Figure 9) . O-HTCC and CS/O-HTCC significantly boosted the expression of sIgA in both the saliva and the vagina compared to Ova alone (P,0.001). In contrast, Ova-specific sIgA was not detectable in the Ova mixed with the Alhydrogel group. The results illustrate that Ova-loaded nanoparticles are a potential candidate as an effective nasal immunoadjuvant of vaccines against respiratory viruses or female genital viruses. 
Conclusion
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